Loading...
•
Dec 31, 2022
Novavax Q4 2022 Earnings Report
Announced financial results for Q4 and twelve months ended December 31, 2022.
Key Takeaways
Novavax reported its Q4 and full year 2022 financial results, highlighting near-term priorities including delivering a competitive product for the 2023 fall vaccination season, reducing the rate of spend and managing cash flow, and leveraging the technology platform to drive additional value.
Identified three near-term priorities: delivering a competitive product for the upcoming 2023 fall vaccination season.
Identified three near-term priorities: reducing rate of spend, managing cash flow, and evolving scale and structure.
Identified three near-term priorities: leveraging technology platform, capabilities, and portfolio of assets to drive additional value beyond Nuvaxovid alone.
Current cash flow forecast for the one-year going concern look forward period estimates that Novavax has sufficient capital available to fund operations, but this forecast is subject to significant uncertainty.
Novavax
Novavax
Forward Guidance
Novavax intends to focus the organization to align investments and activities with the top priority of delivering an updated Covid-19 vaccine for the 2023 fall vaccination season. To maximize opportunities and mitigate the significant risks and uncertainties of the COVID-19 market, Novavax aims to reduce spend, extend cash runway and operate efficiently to best position the company to deliver long-term growth.